These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 30904441)

  • 1. Peptides derived from the extracellular domain of the somatostatin receptor splicing variant SST5TMD4 increase malignancy in multiple cancer cell types.
    Del Rio-Moreno M; Alors-Perez E; Borges de Souza P; Prados-Gonzalez ME; CastaÑo JP; Luque RM; Gahete MD
    Transl Res; 2019 Sep; 211():147-160. PubMed ID: 30904441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin Receptor Splicing Variant
    Fuentes-Fayos AC; G-García ME; Pérez-Gómez JM; Peel A; Blanco-Acevedo C; Solivera J; Ibáñez-Costa A; Gahete MD; Castaño JP; Luque RM
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer.
    Hormaechea-Agulla D; Jiménez-Vacas JM; Gómez-Gómez E; L-López F; Carrasco-Valiente J; Valero-Rosa J; Moreno MM; Sánchez-Sánchez R; Ortega-Salas R; Gracia-Navarro F; Culler MD; Ibáñez-Costa A; Gahete MD; Requena MJ; Castaño JP; Luque RM
    FASEB J; 2017 Nov; 31(11):4682-4696. PubMed ID: 28705809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells.
    Durán-Prado M; Gahete MD; Hergueta-Redondo M; Martínez-Fuentes AJ; Córdoba-Chacón J; Palacios J; Gracia-Navarro F; Moreno-Bueno G; Malagón MM; Luque RM; Castaño JP
    Oncogene; 2012 Apr; 31(16):2049-61. PubMed ID: 21927030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.
    Sampedro-Núñez M; Luque RM; Ramos-Levi AM; Gahete MD; Serrano-Somavilla A; Villa-Osaba A; Adrados M; Ibáñez-Costa A; Martín-Pérez E; Culler MD; Marazuela M; Castaño JP
    Oncotarget; 2016 Feb; 7(6):6593-608. PubMed ID: 26673010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients.
    Gahete MD; Rincón-Fernández D; Durán-Prado M; Hergueta-Redondo M; Ibáñez-Costa A; Rojo-Sebastián A; Gracia-Navarro F; Culler MD; Casanovas O; Moreno-Bueno G; Luque RM; Castaño JP
    Oncotarget; 2016 Sep; 7(37):60110-60122. PubMed ID: 27507050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas.
    Luque RM; Ibáñez-Costa A; Neto LV; Taboada GF; Hormaechea-Agulla D; Kasuki L; Venegas-Moreno E; Moreno-Carazo A; Gálvez MÁ; Soto-Moreno A; Kineman RD; Culler MD; Gahete MD; Gadelha MR; Castaño JP
    Cancer Lett; 2015 Apr; 359(2):299-306. PubMed ID: 25637790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells.
    Molè D; Gentilin E; Ibañez-Costa A; Gagliano T; Gahete MD; Tagliati F; Rossi R; Pelizzo MR; Pansini G; Luque RM; Castaño JP; degli Uberti E; Zatelli MC
    Endocrine; 2015 Nov; 50(2):442-52. PubMed ID: 25854304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors.
    Durán-Prado M; Gahete MD; Martínez-Fuentes AJ; Luque RM; Quintero A; Webb SM; Benito-López P; Leal A; Schulz S; Gracia-Navarro F; Malagón MM; Castaño JP
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2634-43. PubMed ID: 19401364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs.
    Durán-Prado M; Saveanu A; Luque RM; Gahete MD; Gracia-Navarro F; Jaquet P; Dufour H; Malagón MM; Culler MD; Barlier A; Castaño JP
    J Clin Endocrinol Metab; 2010 May; 95(5):2497-502. PubMed ID: 20233783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin, Cortistatin and Their Receptors Exert Antitumor Actions in Androgen-Independent Prostate Cancer Cells: Critical Role of Endogenous Cortistatin.
    Sáez-Martínez P; Porcel-Pastrana F; Pérez-Gómez JM; Pedraza-Arévalo S; Gómez-Gómez E; Jiménez-Vacas JM; Gahete MD; Luque RM
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The truncated isoform of somatostatin receptor5 (sst5TMD4) is associated with poorly differentiated thyroid cancer.
    Puig-Domingo M; Luque RM; Reverter JL; López-Sánchez LM; Gahete MD; Culler MD; Díaz-Soto G; Lomeña F; Squarcia M; Mate JL; Mora M; Fernández-Cruz L; Vidal O; Alastrué A; Balibrea J; Halperin I; Mauricio D; Castaño JP
    PLoS One; 2014; 9(1):e85527. PubMed ID: 24465589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.
    Nölting S; Rentsch J; Freitag H; Detjen K; Briest F; Möbs M; Weissmann V; Siegmund B; Auernhammer CJ; Aristizabal Prada ET; Lauseker M; Grossman A; Exner S; Fischer C; Grötzinger C; Schrader J; Grabowski P;
    PLoS One; 2017; 12(8):e0182852. PubMed ID: 28800359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of human somatostatin receptor 2 domains involved in internalization and signaling in QGP-1 pancreatic neuroendocrine tumor cell line.
    Cambiaghi V; Vitali E; Morone D; Peverelli E; Spada A; Mantovani G; Lania AG
    Endocrine; 2017 Apr; 56(1):146-157. PubMed ID: 27406390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging and therapy of tumors induced to express somatostatin receptor by gene transfer using radiolabeled peptides and single chain antibody constructs.
    Buchsbaum DJ
    Semin Nucl Med; 2004 Jan; 34(1):32-46. PubMed ID: 14735457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: evidence for SSTR2 heterogeneity.
    Taylor JE; Theveniau MA; Bashirzadeh R; Reisine T; Eden PA
    Peptides; 1994; 15(7):1229-36. PubMed ID: 7854974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer.
    Pedraza-Arévalo S; Hormaechea-Agulla D; Gómez-Gómez E; Requena MJ; Selth LA; Gahete MD; Castaño JP; Luque RM
    Prostate; 2017 Nov; 77(15):1499-1511. PubMed ID: 28905400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth.
    Ruscica M; Magni P; Steffani L; Gatto F; Albertelli M; Rametta R; Valenti L; Ameri P; Magnaghi V; Culler MD; Minuto F; Ferone D; Arvigo M
    Mol Cell Endocrinol; 2014 Feb; 382(2):860-70. PubMed ID: 24211300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.